Trial reportArthritis research & therapy2007
Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial.
Trial report in Arthritis research & therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02691949 (Efficacy and Safety of Mycophenolate Mofetil in subjectswithSjogren's Syndrome), which is not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Mycophenolate Mofetil in subjectswithSjogren's Syndrome
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology (Oxford, England) · 2025Guideline
- Pooled it
- Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial.JAMA network open · 2022Trial
- The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.Clinical rheumatology · 2019Trial
- Pediatric Sjögren Disease: Clinical Features, Diagnostic Challenges, and Outcomes in a Single-Centre Romanian Case Series.Journal of clinical medicine · 2026Article
- Executive summary: British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology (Oxford, England) · 2025Article
- Association of focus score and extraglandular involvement in Sjögren's syndrome: A study on antinuclear antibodies and minor salivary gland pathology.Archives of rheumatology · 2024Article
- Mapping the research on Sjögren's syndrome-related dry eye disease: a bibliometric network analysis of the past 20 years.International ophthalmology · 2023Article
- Cardiovascular Involvement in Sjögren's Syndrome.Frontiers in immunology · 2022Review
- Sjogren's Syndrome and Pulmonary Disease.Advances in experimental medicine and biology · 2021Article
- Mycophenolate for the Treatment of Primary Sjögren's Syndrome.Journal of translational internal medicine · 2020Review
- Effectiveness and safety of abatacept for the treatment of patients with primary Sjögren's syndrome.Clinical rheumatology · 2020Observational
- Murine embryonic mesenchymal stem cells attenuated xerostomia in Sjögren-like mice via improving salivary gland epithelial cell structure and secretory function.International journal of clinical and experimental pathology · 2020Article
- A patient presenting with isolated hematuria and renal dysfunction as rare manifestation of cryoglobulinemic glomerulonephritis in the course of autoimmune diseases including Sjögren's syndrome.CEN case reports · 2018Article
- Article
- Infundibuloneurohypophysitis Associated With Sjögren Syndrome Successfully Treated With Mycophenolate Mofetil: A Case Report.Medicine · 2016Article
- Clinical Characteristics and Outcome of Primary Sjogren's Syndrome: A Large Asian Indian Cohort.The open rheumatology journal · 2015Article
- Article
- Topical and systemic medications for the treatment of primary Sjögren's syndrome.Nature reviews. Rheumatology · 2012Review
- Intravenous Immunoglobulin and Mycophenolate Mofetil for Long-Standing Sensory Neuronopathy in Sjögren's Syndrome.Case reports in immunology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the efficacy and safety of mycophenolate sodium (MPS) in patients with primary Sjögren syndrome (pSS) refractory to other immunosuppressive agents. Eleven patients with pSS were treated with MPS up to 1,440 mg daily for an observation period of 6 months in this single-center, open-label pilot trial. At baseline, after 3 months, and after 6 months, we examined the clinical status, including glandular function tests, as well as different laboratory parameters associated with pSS. In addition, subjective parameters were determined on the basis of different questionnaires. Treatment with MPS was well tolerated in 8 of 11 patients. Due to vertigo or gastrointestinal discomfort, two patients did not complete the trial. One patient developed pneumonia 2 weeks after treatment and was withdrawn. In the remaining patients, MPS treatment resulted in subjective improvement of ocular dryness on a visual analogue scale and a reduced demand for artificial tear supplementations. However, no significant alterations of objective parameters for dryness of eyes and mouth were observed, although a substantial improvement of glandular functions occurred in two patients with short disease duration. In addition, treatment with MPS resulted in significant reduction of hypergammaglobulinemia and rheumatoid factors as well as an increase of complement levels and white blood cells. MPS promises to be an additional therapeutic option for patients with pSS, at least in those with shorter disease duration. Further investigations about the efficacy and safety of MPS in pSS have to be performed in larger numbers of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.